Ryo Takeguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ryo Takeguchi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Ryosuke Tanaka
Department of Pediatrics, Asahikawa Medical University, Hokkaido 078-8510, Japan
5 shared publicationsMami Kuroda
Department of Pediatrics, Asahikawa Medical University, Hokkaido 078-8510, Japan
4 shared publicationsMasayuki Itoh
Department of Mental Retardation and Birth Defect Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo 187-8502, Japan
4 shared publications- Satoru Takahashi
Department of Pediatrics, Asahikawa Medical University, 2-1-1-1 Midorigaoka Higashi, Asahikawa City 078-8510, Hokkaido, Japan
4 shared publications Satoru Takahashi
Department of Pediatrics, Asahikawa Medical University, Hokkaido 078-8510, Japan
3 shared publicationsYuichi Akaba
Department of Pediatrics, Asahikawa Medical University, Hokkaido 078-8510, Japan
3 shared publications
Latest Publications
- Open Access
- 22 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 961
Comprehensive High-Depth Proteomic Analysis of Plasma Extracellular Vesicle-Containing Preparations in CDKL5 Deficiency Disorder
Background/Objectives: CDKL5 deficiency disorder (CDD) is a rare X-linked developmental and epileptic encephalopathy characterized by early onset refractory epilepsy and severe neurodevelopmental impairment with autistic features. Despite advances in genetic diagnosis, objective biomarkers reflecting disease mechanisms remain limited. Extracellular vesicles (EVs) circulating in the blood may contain disease-related proteins derived from the central nervous system. This study aimed to characterize the plasma EV proteome in CDD in a hypothesis-generating exploratory framework and identify the candidate molecular pathways associated with this disorder. Methods: Plasma samples from seven patients with genetically confirmed CDD and seven neurotypical developmental controls were analyzed. Extracellular vesicle-containing preparations (EVs-cp) were isolated via immunoprecipitation using antibodies against CD9, CD63, and CD81. Proteomic profiling was performed using data-independent mass spectrometry. Differentially expressed proteins were identified using Welch’s t-test with a false discovery rate correction. Functional enrichment, protein interaction network, and correlation analyses were performed using CDKL5 Clinical Severity Assessment (CCSA) scores. Results: In total, 5617 proteins were identified, of which 3510 were used for quantitative analysis. Compared to the controls, 2108 proteins were upregulated and 158 were downregulated in the CDD samples. Enrichment analysis revealed alterations in vesicle-mediated transport, cytoskeletal organization, and immune-related pathways. Several proteins were also correlated with clinical severity scores. Conclusions: Plasma EV proteomics revealed molecular alterations associated with CDD and provided a potential approach for biomarker discovery and mechanistic investigation.
- 22 April 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (5) , 961
Open AccessComprehensive High-Depth Proteomic Analysis of Plasma Extracellular Vesicle-Containing Preparations in CDKL5 Deficiency Disorder
Background/Objectives: CDKL5 deficiency disorder (CDD) is a rare X-linked developmental and epileptic encephalopathy characterized by early onset refractory epilepsy and severe neurodevelopmental impairment with autistic features. Despite advances in genetic diagnosis, objective biomarkers reflecting disease mechanisms remain limited. Extracellular vesicles (EVs) circulating in the blood may contain disease-related proteins derived from the central nervous system. This study aimed to characterize the plasma EV proteome in CDD in a hypothesis-generating exploratory framework and identify the candidate molecular pathways associated with this disorder. Methods: Plasma samples from seven patients with genetically confirmed CDD and seven neurotypical developmental controls were analyzed. Extracellular vesicle-containing preparations (EVs-cp) were isolated via immunoprecipitation using antibodies against CD9, CD63, and CD81. Proteomic profiling was performed using data-independent mass spectrometry. Differentially expressed proteins were identified using Welch’s t-test with a false discovery rate correction. Functional enrichment, protein interaction network, and correlation analyses were performed using CDKL5 Clinical Severity Assessment (CCSA) scores. Results: In total, 5617 proteins were identified, of which 3510 were used for quantitative analysis. Compared to the controls, 2108 proteins were upregulated and 158 were downregulated in the CDD samples. Enrichment analysis revealed alterations in vesicle-mediated transport, cytoskeletal organization, and immune-related pathways. Several proteins were also correlated with clinical severity scores. Conclusions: Plasma EV proteomics revealed molecular alterations associated with CDD and provided a potential approach for biomarker discovery and mechanistic investigation.
- 18 August 2022
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 441, 120381
Structural and functional changes in the brains of patients with Rett syndrome: A multimodal MRI study
- 18 August 2022
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 441, 120381
Structural and functional changes in the brains of patients with Rett syndrome: A multimodal MRI study
- 1 March 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 422, 117321
Early diagnosis of MECP2 duplication syndrome: Insights from a nationwide survey in Japan
- 1 March 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 422, 117321
Early diagnosis of MECP2 duplication syndrome: Insights from a nationwide survey in Japan
- 1 September 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 416, 117041
The role of molecular analysis of SLC2A1 in the diagnostic workup of glucose transporter 1 deficiency syndrome
- 1 September 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 416, 117041
The role of molecular analysis of SLC2A1 in the diagnostic workup of glucose transporter 1 deficiency syndrome
- Open Access
- 9 December 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (2)
MeCP2_e2 partially compensates for lack of MeCP2_e1: A male case of Rett syndrome
Background: Rett syndrome (RTT) is a neurodevelopmental disorder that predominantly affects girls. Its causative gene is the X‐linked MECP2 encoding the methyl‐CpG‐binding protein 2 (MeCP2). The gene comprises four exons and generates two isoforms, namely MECP2_e1 and MECP2_e2. However, it remains unclear whether both MeCP2 isoforms have similar function in the brain.Methods: We report a case of a boy with typical RTT. Male cases with MECP2 variants have been considered inviable, but somatic mosaicism of the variants can cause RTT in males. Whole‐exome sequencing was performed to search for the genetic background.Results: A novel nonsense and mosaic variant was identified in exon 1 of MECP2, and the variant allele fraction (VAF) was 28%. Our patient had the same level of VAF as that in reported male cases with mosaic variants in MECP2 exon 3 or 4, but manifested RTT symptoms that were milder in severity compared to those in these patients.Conclusion: This is probably because the variants in MECP2 exon 3 or 4 disrupt both isoforms of MeCP2, whereas the variant in exon 1, as presented in this study, disrupts only MeCP2_e1 but not MeCP2_e2. Therefore, our findings indicate that MeCP2_e2 may partially compensate for a deficiency in MeCP2_e1.
- 9 December 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (2)
Open AccessMeCP2_e2 partially compensates for lack of MeCP2_e1: A male case of Rett syndrome
Background: Rett syndrome (RTT) is a neurodevelopmental disorder that predominantly affects girls. Its causative gene is the X‐linked MECP2 encoding the methyl‐CpG‐binding protein 2 (MeCP2). The gene comprises four exons and generates two isoforms, namely MECP2_e1 and MECP2_e2. However, it remains unclear whether both MeCP2 isoforms have similar function in the brain.Methods: We report a case of a boy with typical RTT. Male cases with MECP2 variants have been considered inviable, but somatic mosaicism of the variants can cause RTT in males. Whole‐exome sequencing was performed to search for the genetic background.Results: A novel nonsense and mosaic variant was identified in exon 1 of MECP2, and the variant allele fraction (VAF) was 28%. Our patient had the same level of VAF as that in reported male cases with mosaic variants in MECP2 exon 3 or 4, but manifested RTT symptoms that were milder in severity compared to those in these patients.Conclusion: This is probably because the variants in MECP2 exon 3 or 4 disrupt both isoforms of MeCP2, whereas the variant in exon 1, as presented in this study, disrupts only MeCP2_e1 but not MeCP2_e2. Therefore, our findings indicate that MeCP2_e2 may partially compensate for a deficiency in MeCP2_e1.